Bicalutamide with BCG for bladder cancer after BCG treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older
- You have biopsy-proven non-muscle-invasive bladder cancer
- Your urologist has recommended starting BCG treatment through the bladder
- You received certain chemo instillations right after surgery (gemcitabine, epirubicin, or mitomycin C)
- If you have a partner who could become pregnant, you must use two reliable birth-control methods during the study and for at least 3 months after stopping the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests whether radiation therapy can help people with early-stage bladder cancer that has a high risk of coming back. It may be an option for those who have not tried BCG treatment.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.